NewAmsterdam Pharma Co N.V (NAMS) Non-Current Deffered Revenue: 2022-2024
- NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue rose 2191.02% to $222,000 in Q2 2024 from the same period last year, while for Jun 2024 it was $222,000, marking a year-over-year increase of 2191.02%. This contributed to the annual value of $1.0 million for FY2023, which is 78.74% down from last year.
- Latest data reveals that NewAmsterdam Pharma Co N.V reported Non-Current Deffered Revenue of $222,000 as of Q2 2024, which was down 50.00% from $444,000 recorded in Q1 2024.
- NewAmsterdam Pharma Co N.V's 5-year Non-Current Deffered Revenue high stood at $4.8 million for Q4 2022, and its period low was $9,690 during Q2 2023.
- Over the past 3 years, NewAmsterdam Pharma Co N.V's median Non-Current Deffered Revenue value was $444,000 (recorded in 2024), while the average stood at $1.3 million.
- In the last 5 years, NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue slumped by 78.74% in 2023 and then skyrocketed by 2,191.02% in 2024.
- Quarterly analysis of 3 years shows NewAmsterdam Pharma Co N.V's Non-Current Deffered Revenue stood at $4.8 million in 2022, then tumbled by 78.74% to $1.0 million in 2023, then soared by 2,191.02% to $222,000 in 2024.
- Its Non-Current Deffered Revenue was $222,000 in Q2 2024, compared to $444,000 in Q1 2024 and $1.0 million in Q4 2023.
